Jiangsu Hengrui Pharmaceuticals (600276.SH) signs SHR-4849 project licensing agreement with IDEAYA Biosciences.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has reached an agreement with IDEAYA Biosciences to license the proprietary Type 1 new drug injection SHR-4849 (referred to as "SHR-4849") project to IDEAYA Biosciences for compensation. SHR-4849 is a targeted antibody-drug conjugate (ADC) developed independently by Hengrui with intellectual property rights, targeting DLL3, with a payload of topoisomerase inhibitor (TOPOi). The company stated that the signing of this agreement will help expand the overseas market for SHR-4849, provide quality treatment options for global patients, and further enhance the company's innovative brand and overseas performance. The company emphasizes both independent research and open cooperation, strengthening international cooperation on the basis of endogenous development to achieve rapid transformation of research and development achievements, leveraging international leading partners to cover overseas markets and accelerate integration into the global drug innovation network to maximize product value and serve global patients with innovative products.